

Index

Note: Figures and Tables are indicated by *italic page numbers*; CAP = community-acquired pneumonia; HAP = hospital-acquired pneumonia; HCAP = healthcare-associated pneumonia; ICU = intensive care unit; MRSA = methicillin-resistant *Staphylococcus aureus* infections; VAP = ventilator-associated pneumonia

- Acinetobacter anitratus*, in VAP, 69
- Acinetobacter baumannii*
- epidemiological characteristics, 133–134
 - microbiological characteristics, 131–133
 - resistance to antimicrobials, 132–133, 133
 - transmission mechanisms, 139
 - in VAP, 19, 44, 83, 218
- Acinetobacter baumannii* pneumonia, 131–143
- clinical characteristics, 134
 - prevention of, 139
 - treatment of, 134–138
- Acinetobacter* spp
- in VAP, 19, 44, 69, 83, 95
 - failure of therapy, 247
- acute lung injury (ALI) patients, effect of prone position, 17
- acute respiratory distress syndrome (ARDS) patients
- clinical features of LRT infection, 236
 - detection of failure to respond, 251
 - effect of prone position, 17
 - MRSA infection, 113, 239
 - risk of pneumonia, 99, 216
 - VAP in
 - causative microorganisms, 239–240
 - diagnosis, 235–236
 - incidence, 236–239
 - mortality and morbidity, 240–241
- aerodigestive tract, decolonization of, 14, 24–27, 262
- alcoholism, as risk factor, 216
- allergic reactions, 151
- American Thoracic Society (ATS)
- definition of HCAP, 4
 - guidelines on HAP management, 45, 116, 224, 225, 246
- amikacin, 53, 84, 87, 133, 135, 136, 137, 225
- aminoglycosides, 135, 178–179
- see also* amikacin; gentamicin; tobramycin
- amphotericin B
- digestive decontamination using, 25, 221
 - fungal infections treated with, 148, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166
- ampicillin, 133, 224, 225
- anaerobic microorganisms, in VAP, 44, 95
- antibiogram procedures, 53
- antibiotic policy, 15, 27–28

- antibiotic therapy
 de-escalation of, 87
 optimising, 86–88, 174
 shortening of duration, 87–88
- antibiotic tolerance, 250
- antimicrobials
 classification, 175–187
 concentration-dependent/
 time-dependent, 176–179
 hydrophilic/lipophilic, 179–180
 pharmacokinetic/pharmacodynamic
 (PK/PD) principles, 174
 application to maximizing drug
 exposure, 180–184
- ARDS, *see* acute respiratory distress
 syndrome (ARDS) patients
- Argentina, cost studies, 277, 278
- artificial airway management, in VAP
 prevention strategy, 13–14, 18–21
- artificial airways, colonization of, 67–69
- aspergilloma, 151
- Aspergillus* antigenemia testing, 207
- Aspergillus* pneumonia, 45, 85,
 150–160
 clinical manifestations, 153–154
 clinical syndromes caused by, 151
 epidemiology, 150–152
 pathogenesis, 152–153
 prophylaxis, 159–160
 treatment of, 157–159
see also invasive aspergillosis
- Aspergillus* spp., 150
 A. flavus, 152
 A. fumigatus, 151, 152, 153
 toxins produced by, 153
- AUC/MIC ratio, 176–177
 vancomycin, 115, 176
- autoinducers (in quorum sensing system),
 98
- azithromycin, 180, 182
- bacteraemia, relationship to pneumonia, 70
- barbiturate sedation, in trauma patients, 216
- beta-glucan, detection in invasive
 aspergillosis, 157
- beta-lactams, 87, 102, 114
 effect on galactomannan assay (for
 aspergillosis), 156
 resistance of *S aureus* to, 112
- biofilm, 20, 68, 71, 112, 258
 formation by *P. aeruginosa*, 20, 98, 259
 limitation of formation, 20, 258–259
 scattering into lungs, 68
- Blastomyces dermatitidis*, 163
- blastomycosis, 160, 162–163
 clinical manifestations, 160, 162–163
 diagnosis, 160, 163
 treatment of, 160, 163
- blood cultures, 50, 82, 222–223
 antibiogram procedures using, 53
- body position, effects, 17–18, 65–67
- bone marrow transplant patients
 acute respiratory failure, 192
 bronchoscopy findings, 197
 fungal infections, 146, 155
 radiology findings, 201
- broad-spectrum antibiotics, 115, 117, 118,
 121–122
 change to narrow/targeted agents, 28,
 87, 246
 effects of unnecessary use, 27, 203,
 246, 258
 in empiric(al) therapy, 28, 43, 82, 85,
 100, 173, 240, 242
 minimum use recommended, 8, 82
- bronchoalveolar lavage (BAL), 46, 48–49, 50
 in ARDS patients, 237
 and Gram stain, 51
 unreliability for some patients, 49
 compared with other sampling
 techniques, 47, 49
- bronchoscopic sampling techniques,
 compared with nonbronchoscopic
 techniques, 46–47
- bronchoscopy
 diagnostic strategy without, 197–208
 with bronchoalveolar lavage (FO–BAL),
 196–197
- calibrated loop technique, 53
- cancer patients with pulmonary infiltrates
 diagnostic strategies, 194–208
 bronchoscopy with bronchoalveolar
 lavage, 196–197
 DIRECT Approach, 194–195
 future research, 207–208
 non-bronchoscopy investigations,
 197–207

- cancer patients, pulmonary complications, 192
- Candida* pneumonia, 145, 146–150
 clinical manifestations, 147
 diagnostic strategies, 147
 epidemiology, 146
 histological findings, 74
 histopathology, 148
 treatment of, 148
- Candida* spp., 45, 146
C. albicans, 145, 146
 relevance of presence in respiratory tract, 148–150, 218–219
- carbapenem antibiotics, 84, 87, 102, 135, 224
- carbapenem-resistant *A. baumannii*, 132
- carbapenem-resistant *A. baumannii* pneumonia, treatment of, 136–138
- carbapenem-susceptible *A. baumannii* pneumonia, treatment of, 135
- casprofungin, 148, 158, 159
- CB-181963* investigational antibiotic, 122
- cefepime, 53, 102, 133, 225
- cefotaxime, 221, 226
- ceftazidime, 102, 133, 225
 pharmacokinetic/pharmacodynamic considerations, 182, 183, 186
- ceftobiprole, 118, 121–122
- ceftriaxone, 180, 224, 225
- cefuroxime, 221, 223, 224, 225, 226
- Centers for Disease Control and Prevention
 contact precautions recommended, 111
 recommendations on prevention of HAP/VAP, 13–14, 21
- cephalosporins, 84, 87, 223–224, 225
- chest radiography, 100, 113, 147, 155, 197–199, 222
- Chlamydia pneumoniae*, diagnosis of infection, 205
- Chlamydomydia pneumoniae*, 7
- Chloramphenicol, 179
- chlorhexidine, use in oral care, 24–25
- chronic granulomatous disease (CGD) patients
 fungal infections, 152
 prophylaxis, 158
- chronic obstructive pulmonary disease (COPD) patients
 lower airway colonization in, 67
 risk of pneumonia, 99, 100
 sampling technique(s) recommended, 49
- ciprofloxacin, 53, 84, 87, 102, 133, 180, 221, 225
- clarithromycin, 182
- clinical characteristics, various pneumonias, 5, 100
- clinical pulmonary infection score (CPIS), 86, 223, 247
- clinical resolution
 in HAP, 85–86, 246
 mean time taken, 246
- cloxacillin, 114
- co-trimoxazole, 111
- Coccidioides immitis*, 163
- coccidioidomycosis, 161, 163–164
 clinical manifestations, 161, 163
 diagnosis, 161, 164
 treatment of, 161, 164
- colistin, 24–25, 84–85, 133, 136–137, 221
see also polymyxin E
- colistin-resistant *A. baumannii*, 132, 133
- colonization
 artificial airways, 67–69
 by MRSA, 110–111
 gastric, 65
 lower airway, 67
 nasal, 64, 110, 111
 oropharyngeal, 5, 24, 64–65, 95–96
 relationship to (subsequent) infection, 69, 252
- colony-stimulating factors (CSFs), 158–159
- comatose patients, MSSA infection risk, 83, 84, 109–110, 223
- combination therapy, aspergillosis treated, 158
- community-acquired pneumonia (CAP)
 causal microorganisms, 6, 7
 compared with HCAP, 6
 definition, 1, 63
- compensatory anti-inflammatory response syndrome (CARS), 263
- computed tomography (CT), *see* high-resolution computed tomography (HRCT)

- concentration-dependent antimicrobials, 178–179, 251
 pharmacodynamic determinants of efficacy, 178
see also aminoglycosides; fluoroquinolones
- construction work, preventive measures during, 159
- continuous subglottic suctioning (CSS), cost effectiveness, 279–280
- corticosteroids, fungal infections affected by, 151, 153
- cost
 meaning of various terms, 274–275
 compared with charge(s), 274
- cost-effectiveness analysis (CEA), 275, 279–282
 prevention strategies, 279–281
 treatment alternatives, 281–282
- cost minimization, 274–275
 continuous subglottic suctioning
 example, 279–280
 kinetic therapy vs lateral rotation, 280
- cost studies
 HAP/VAP
 administrative database studies, 275–276
 limitations, 275, 278
 microcosting, 278–279
 non-US studies, 277–278
 single institution studies, 276–277
 US studies, 275–277
- cost-utility analysis, 275
- cost-benefit analysis, 275
- critically ill patients, antibiotic dose adjustment 184–187
- cultures
 conventional, 53–54
 rapid, 52–53
- cystic fibrosis patients
A. baumannii infections, 136–137
 risk of pneumonia, 99
- cytomegalovirus (CMV), 45, 206
- dalbavancin, 119, 122
- dalfopristin/quinupristin mixture, 84, 114, 117, 120
- daptomycin, 84, 114, 117, 121
- de-escalation therapy, 28, 87, 173
- digestive tract, selective decontamination of, 14, 24–25
- dimorphic fungi, 160–166
- dominant strategy (health economics), 280
- doxycycline, 133, 136
- drug-induced pneumonitis, HRCT findings, 201, 203
- DX 619 investigational antibiotic, 123
- E-test sensitivity analysis, 53, 82
- early-onset pneumonia
 causal microorganisms, 67, 94, 107, 218
 risk factors, 64, 69, 83, 84, 109–110, 216
- echinocandins, 158
- empiric(al) therapy, 1
 antibiotic therapy, 28, 43, 82, 84, 85, 100, 173, 225, 240, 242
 antifungal therapy, 158
 de-escalation of, 28, 87, 173
 failure to respond to, 245
 HCAP compared with CAP, 8
P. aeruginosa pneumonia, 101–103
 trauma patients, 225, 226
- endemic mycoses, 160–166
- endotoxin tolerance, 263
- endotracheal aspiration (sampling), 46, 48
 and Gram stain, 51
 and lower airway colonization, 67
 compared with other sampling techniques, 47, 48
- endotracheal intubation
 complications, 69
 as risk factor for VAP, 22–23
- endotracheal tubes
 biofilm on, 20, 68, 71, 112, 258
 colonization of, 68–69, 262
 cuff pressure, effect on VAP risk, 19–20, 219
 silver-coated, 20, 262
- enteral feeding, prevention of aspiration, 14
- Enterobacter* spp., in VAP, 95, 218
- Enterobacteriaceae*
 in HAP, 85
 in healthcare-associated infections, 3, 19
 in VAP, 19, 44, 94, 95, 218, 239
 failure of therapy, 247
- Enterococcus* spp., in VAP, 95
- ertapenem, 224, 225

- Escherichia coli*
 in HCAP, 3, 5
 in VAP, 95, 218
 everninomycin, 123
 extubation, respiratory failure after, 23
- failure to respond (to antibiotic therapy)
 causes, 248, 249–251
 microbiological related factors, 248, 249–250
 patient-related factors, 248, 249
 treatment-related factors, 250–251
 definition, 246–247
 diagnosis, 251–252
 biochemical response, 252
 clinical response, 251–252
 microbiologic response, 252
 frequency, 247
 management of, 253
 microbiologic etiology, 247–248
 noninfectious etiology, 248–249
- fibre-optic bronchoscopy with
 bronchoalveolar lavage (FO–BAL), 46, 48–49
 cancer patients with pulmonary infiltrates, 196–197
 compared with other sampling techniques, 47
- fluconazole, 145, 146, 148, 159, 161, 163, 164
- fluoroquinolones, 102, 178, 224
- fungal pneumonia, 145–172
 diagnosis, 200–201, 207
 HRCT findings, 147, 155, 156, 200–201, 201
 see also Aspergillus pneumonia; Candida pneumonia
- fungi, in VAP, 45, 95
- galactomannan assay
 in diagnosis of aspergillosis, 155–156, 207
 effect of antifungal therapy, 156
- gastric colonization, 65
- gastric contents, aspiration of, 66–67, 96–97
- gatifloxacin, 180
- gentamicin, 25, 221, 225
- German hospitals, cost studies, 277
- Glasgow Coma Scale (GCS), as risk factor, 216, 217
- gloving, recommendations, 13
- glycopeptide antibiotics
 MRSA pneumonia treated with, 84, 115, 116–117, 181
 pharmacokinetic/pharmacodynamic considerations, 181, 183
 see also teicoplanin; vancomycin
- graft-versus-host disease (GVHD), HRCT findings, 201, 202
- Gram-negative bacteria
 in HCAP, 3, 5
 oropharyngeal colonization by, 5, 24, 64–65
 quorum sensing system, 98–99
 in VAP, 19, 24, 44, 239
 see also Acinetobacter baumannii; Enterobacteriaceae; Escherichia coli; Klebsiella pneumoniae; Pseudomonas aeruginosa
- Gram stain, information provided by, 51–52, 81
- granulocyte colony stimulating factor (G-CSF), 264–265
- granulocyte macrophage colony stimulating factor (GM-CSF), 265
- H₂-antagonists, 27, 65
- Haemophilus influenzae*
 in CAP, 6, 6
 in HCAP, 6, 6
 lower airway colonization by, 67
 in VAP, 19, 69, 95, 218, 223
- Haemophilus spp.*, oropharyngeal colonization by, 24
- hand hygiene, effect on VAP, 13, 16–17
- head injury patients, pneumonia in
 causative pathogens, 218–219
 risk factors, 69, 109–110, 215–217
- healthcare-associated infections, 3
- healthcare-associated pneumonia (HCAP), 5–7
 causal microorganisms, 5–7
 compared with CAP, 6
 clinical characteristics, 5
 cost studies, 276
 definitions, 3–4, 4, 11, 276
 guideline definition, 8–9
 microbiology, 5–7
 outcomes, 7–8

- heat and moisture exchangers (HME)
 contra-indications, 22
 compared with heated humidifiers, 13, 22
- herpes simplex virus (HSV) pneumonia,
 45, 206
- herpes virus pneumonia, diagnosis, 206
- heteroresistance, 250
- hexetidine, 25
- high-efficiency particulate air (HEPA)
 filters, 159
- high-resolution computed tomography
 (HRCT), 199–203
 findings, 200–203
 bacterial pneumonia, 200, 201
 drug-induced pneumonitis, 201, 203
 fungal pneumonia, 147, 155, 156,
 200–202, 201
 graft-versus-host disease, 201, 202
 pneumocystis, 201, 202
 radiation-induced toxicity, 201,
 202–203
 tuberculosis, 201, 202
 viral pneumonia, 201, 202
- histopathology, phases of pneumonia, 72
- histoplasmosis, 160, 161–162
 clinical manifestations, 160, 162
 diagnosis, 160, 162
 pathogenesis, 162
 treatment of, 160, 162
- hospital-acquired pneumonia (HAP)
 best initial management measures, 82–85
 clinical approach, 79–91
 clinical resolution, 85–86
 cost studies, 275–279
 administrative database studies,
 275–276
 European studies, 277
 limitations, 275, 278
 microcosting, 278–279
 single institution studies, 276–277
 South American studies, 277–278
 US studies, 275–277
 definition, 1, 11, 63
 diagnosis, 15, 54, 80, 81–82
 epidemiology, 109–111
 incidence, 79
 mortality rates, 7, 273
 pathogenesis, 12, 19, 24, 63–64, 112
 pathophysiology, 63–78, 80–81
 prevention of, 111–112
 treatment of, 114–123
- humidification systems, in ventilator
 management, 13, 21–22
- hydrophilic antibiotics, 179, 179–180
 pharmacokinetic/pharmacodynamic
 considerations, 181, 182, 183
see also aminoglycosides; beta-lactams;
 glycopeptide antibiotics
- hypoalbuminaemia, antibiotic efficacy
 affected by, 186
- iclaprim, 118–119, 123
- imipenem, 53, 84, 102, 133, 135,
 136, 225
- imipenem-resistant *A. baumannii*, 132,
 133, 136
- immunocompromised patients
 fungal infections, 147, 152, 157,
 162, 163
 minimally invasive diagnostic strategy,
 191–214
 risk of pneumonia, 94, 99
- immunomodulatory strategies, recurrent
 VAP, 264–266
- immunoparalysis, 249, 263–264
- immunosuppressive therapy, fungal
 infections affected by, 151
- inappropriate therapy, 173
 as risk factor, 218, 246
S. aureus as surrogate marker, 8
- infection control, in prevention of VAP,
 16, 27
- infection, relationship to colonization,
 69, 252
- Infectious Diseases Society of America
 (IDSA)
 definition of HCAP, 4
 guidelines
 on fungal infections, 148, 162,
 163, 164
 on HAP management, 45, 116, 224,
 225, 246
- infectious maxillary sinusitis (IMS), 70
- injury severity score (ISS), as risk factor,
 216, 217
- intensive care unit (ICU)
 excessive use of antibiotics, 43
 staffing levels recommendations, 16

- interferon gamma, 264, 265–266
- interleukin-10 (IL-10) 263
- intubation-associated pneumonia, 63
see also ventilator-associated pneumonia (VAP)
- intubation, as risk factor, 22–23, 215
- invasive aspergillosis, 151, 152, 153
 clinical manifestations, 153–154
 diagnosis, 154–157, 200–201, 207
 prophylaxis, 159–160
 treatment of, 157–159
- itraconazole, 158, 159, 160, 161, 162, 163, 164, 166
- Kaplan–Meier estimates, probability of
 VAP with/without ARDS, 238
- ketoconazole, 163, 164
- kinetic bed therapy, and VAP incidence, 14, 18
- Klebsiella pneumoniae*, 3, 5, 95, 218
- laboratory diagnosis
 bacterial infections, 203–205
 fungal infections, 207
 pneumocystis pneumonia, 206–207
 VAP, 43–62
 viral infections, 205–206
- late-onset pneumonia
 causal microorganisms, 94, 100, 133, 218
 risk factors, 64, 69, 218
- lateral rotation therapy, 18
 costs compared with kinetic therapy, 280
- Legionella pneumophila*, 85, 85, 218
 tests, 203–204
- Legionella* spp., 7, 8
- length of stay, comparison (CAP/HAP/VP), 7, 7, 9, 277, 278
- leukaemia patients, factors affecting drug disposition, 186
- levofloxacin, 102, 180, 224, 225
 pharmacokinetic/pharmacodynamic considerations, 182, 183–184
- linezolid, 84, 114, 116, 120, 225
 pharmacokinetic/pharmacodynamic considerations, 182, 183
 compared with vancomycin, 84, 116, 117, 253, 281–282
- lipophilic antibiotics, 179, 179, 180
 pharmacokinetic/pharmacodynamic considerations, 182, 183
see also; fluoroquinolones; linezolid; rifampicin
- lower airway colonization, 67
- lower respiratory tract (LRT) samples, 82
 quality, 81
 techniques, 45–50
- lung biopsy cultures, 50
 and histological findings, 74–75
 as last resort, 50, 208
 superseded by FO–BAL, 50, 196
- lung contusion, VAP caused by, 217
- lysostaphin, 112, 123
- macrolides, 118, 176, 179, 180
- mechanical ventilation duration
 in ARDS patients, 240, 241
 VAP incidence affected by, 29, 216, 240, 241
see also prolonged-ventilation patients
- mechanical ventilation management, 13, 21–23
- meropenem, 84, 133, 225
 pharmacokinetic/pharmacodynamic considerations, 182, 183
- metallo- β -lactamases (MBLs), 261
- methicillin-resistant *Staphylococcus aureus* (MRSA), 3, 107–108
 CAP compared with HCAP, 6, 7
 cost implications, 281
 effect of SDD therapy, 26
 nasal carriers, 64
 patients susceptible to, 110–111
 treatment agents, 84, 115–123
 in VAP, 83, 84, 109, 113, 114, 239, 261
 failure of therapy, 247
 compared with MSSA, 108, 281
- methicillin-resistant *Staphylococcus aureus* (MRSA) pneumonia
 epidemiology, 109
 prevention of, 111–112
 risk factors, 110–111
- methicillin-sensitive *S. aureus* (MSSA), 107
 CAP compared with HCAP, 6
 in comatose patients, 83, 84, 109–110, 223
 in VAP, 109
 compared with MRSA, 108

- methicillin-sensitive *S. aureus* (MSSA)
 pneumonia
 epidemiology, 109
 risk factors, 109–110
 metronidazole, 224, 230
 microbiology laboratory
 conventional cultures, 53–54
 Gram staining, 51–52
 information/interpretation from, 54
 pre-emptive rapid cultures, 52–53
 role in diagnosis of VAP, 43–62
 sampling techniques, 45–50
 transport of samples, 50–51
 microcosting, 278–279
 minimum inhibitory concentration (MIC),
 176
 antibiogram results, 53
 various antibiotics, 116, 118, 121, 122,
 123, 132, 136
 monoamino oxidase (MAO), inhibitory
 effects of linezolid, 116, 120
 mortality rates
 effect of SDD therapy, 221
 fungal pneumonia, 145, 149, 152
 HAP/HCAP, 7, 7, 273
 immunocompromised patients, 192
 MRSA infections, 84, 113
 VAP, 12, 87, 134, 247, 257
 moxifloxacin, 224
 MRSA, *see* methicillin-resistant
 Staphylococcus aureus (MRSA)
 mucormycosis, 200
 multi-resistant *A. baumannii*, treatment of,
 138
 multidrug-resistant (MDR) pathogens, 3
 antibiotic policy to reduce emergence,
 27, 28, 80, 245, 247
 risk factors for, 3, 80, 223, 224
 mupirocin, 111, 112
Mycoplasma pneumoniae, 7
 diagnosis, 204–205

 nasal intubation, compared with oral route,
 13, 18
 nasogastric tube fed patients, 5
 nasogastric tube, and oropharyngeal
 aspiration, 65
 neuro-trauma patients, early onset
 pneumonia, 83, 84, 109–110

 non-bronchoscopic diagnostic strategy,
 197–207
 non-bronchoscopic sampling techniques,
 46–47, 47
 non-invasive positive pressure ventilation
 (NPPV), 13, 23
 non-optimal medical care, 15–16
 nonresolving nosocomial pneumonia, 246
 see also failure to respond (to antibiotic
 therapy)
 nosocomial pneumonia, *see*
 hospital-acquired pneumonia (HAP)
 nursing home patients
 atypical pathogen pneumonia, 8
 HCAP incidence, 5
 infection rate compared with
 community, 2

 occult resistance, as cause of failure to
 respond, 249–250
 oral intubation, compared with nasal route,
 13, 18
 organ transplant patients, fungal infections,
 146, 151, 151, 152, 162, 163, 165
 oritavancin, 119
 oropharyngeal colonization, 5, 24, 64–65,
 95–96, 218
 in alcoholic patients, 216, 228
 modulation of, 14, 24–25, 220
 oropharyngeal secretions, aspiration of,
 65–66
 outcomes, HCAP compared with CAP
 patients, 7–8
 oxacillin, 53, 180
 oxacillin-resistant VAP, 181
 oxazolidinones, *see* linezolid
 oxygenation, improvement in, as response
 criterion, 251

 pan-resistant *A. baumannii*, 132
 treatment of, 138, 138
 Panton–Valentine leukocidin gene,
 109, 250
Paracoccidioides brasiliensis, 165
 paracoccidioidomycosis, 161, 165
 clinical manifestations, 161, 165
 diagnosis, 161, 165
 pathogenesis, 165
 treatment of, 161, 165

- pathophysiology
 HAP/VAP, 63–78, 80–81
 MRSA VP, 112
- patient positioning, effects, 17–18, 65–67, 219
- penicillin-binding proteins (PBPs), 112
- penicilliosis, 161, 164–165
 clinical manifestations, 161, 164
 diagnosis, 161, 164
 treatment of, 161, 165
- Penicillium marneffei*, 164
- pharmacokinetic/pharmacodynamic (PK/PD) principles
 antimicrobials, 174
 application to maximizing drug exposure, 180–184
- pharmacokinetics, suboptimal, 251
- pharmacological considerations, 173–189
- pheromones, 98
- piperacillin, 102, 133
- piperacillin/tazobactam combination, 53, 84, 87, 225
- plugged telescoping catheter (PTC)
 and Gram stain results, 52
 compared with other sampling techniques, 47
- pneumocystis pneumonia (PCP)
 diagnosis, 201, 202, 206–207
 HRCT findings, 201, 202
- polymerase chain reaction (PCR) tests
 for bacteria, 204–205
 for viruses, 205–206
- polymyxin B, 25, 136, 221
- polymyxin E, 25, 136
see also colistin
- posaconazole, 158, 164
- positive pressure ventilation rooms, 159
- post-antibiotic effect (PAE), various antibiotics, 115, 118, 119, 121, 122, 123, 176
- post-sepsis immunodepression, 263
- pre-emptive rapid cultures, 52–53
- preventive strategies, HAP/VAP, 12–29
- prior antibiotic exposure, as risk factor, 3, 64, 80, 84, 94, 108, 109, 110, 218
- procalcitonin, as marker in VAP, 241, 252, 262
- prolonged-ventilation patients
 MRSA pneumonia risk, 84, 109, 110
P. aeruginosa pneumonia risk, 84, 99
 sampling technique(s), 49
 VAP risk, 84, 99, 109, 110, 239, 259, 261, 266
- prone position (of patient), VAP incidence affected by, 17–18
- protected specimen brush (PSB)
 sample, 48
 ARDS patients, 237
 and Gram stain, 51
 compared with other sampling techniques, 47, 49
- protein secretion factors, in *P. aeruginosa* infection, 97–98
- Proteus* spp., in VAP, 95, 218
- Pseudomonas aeruginosa*
 biofilm formation by, 20, 98, 259
 in CAP, 6, 6
 in HAP, 85
 in HCAP, 3, 5, 6, 6
 lower airway colonization by, 67, 97
 quorum sensing system, 98–99
 in recurrent VAP, 259
 treatment agents, 84
 in VAP, 19, 20, 44, 83, 93–105, 218, 239
 failure of therapy, 247
 virulence factors, 97–99, 97, 261
- Pseudomonas aeruginosa* pneumonia, 93–105
 clinical manifestations, 100
 empiric(al) antibiotic therapy, 101–103
 mortality, 101
 pathogenesis, 95–99
 prognostic factors, 101
 recurrent, 259, 260
 risk factors, 99–100
- pulmonary infiltrates, causes in cancer patients, 192–193
- quality-adjusted life-year (QALY) concept, 275
 linezolid vs vancomycin example, 282
- quinupristin/dalfopristin mixture, 84, 114, 117, 120
- quorum sensing, 98–99, 250

- radiation-induced toxicity, HRCT findings, 201, 202–203
- radiographical investigations
 chest radiography, 197–199
 high-resolution computed tomography, 199–203
- ranitidine, 27, 65
- re-intubation, as risk factor, 219, 220
- recombinant interferon gamma, 158
- recurrent VAP, 257–272
 clinical impact, 261
 epidemiology, 259
 genetic predisposition, 263–264
 immunomodulatory strategies, 264–266
 pathogenesis, 258
 prevalent microorganisms, 259
 prevention measures, 262–263
 prognosis, 261–262
 risk factors, 260–261
- red blood cell (RBC) transfusion, as risk factor, 28–29
- renal impairment, antibiotic efficacy affected by, 84, 186
- resolution of clinical parameters, in HAP, 85–86
- rifampicin, 85, 133, 137
- rotational/kinetic bed therapy, and VAP incidence, 14, 18
- salvage therapy
 fungal infections, 157, 158
 VAP, 253
- sampling techniques, microbiological, 45–50
 bronchoscopic vs. nonbronchoscopic, 46–47
 surveillance cultures, 45–46
- sedation, effect on VAP incidence, 29
- selective decontamination of digestive tract (SDD), 25, 221
 effect on VAP, 14, 25–26, 112, 220–222
 recommendations on use, 26
- semi-recumbent position (of patient), effects, 17, 66, 66, 219
- septic shock, 98, 134
- serial dilution technique, 53
- Serratia* spp., in VAP, 95, 218
- silver-coated endotracheal tubes, 20, 262
- sinusitis
 as complication of endotracheal intubation, 69
 relationship to pneumonia, 18, 69–70
- Sporothrix schenckii*, 165
- sporotrichosis, 161, 165–166
 management/treatment guidelines, 161, 166
 means of infection, 165–166
- staff education (on HAP/VAP prevention), 13, 16
 cost savings resulting, 281
 staffing levels in ICU, recommendations, 16
- Staphylococcus aureus*
 beta-lactam resistance, 112
 in CAP, 6, 6
 in HAP, 85, 107–129, 203
 in HCAP, 3, 5–6, 6
 lower airway colonization by, 67
 as marker for inappropriate therapy, 8
 microbiology, 108–109
 nasal colonization by, 64
 oropharyngeal colonization by, 24
 in VAP, 44, 69, 95, 218
see also methicillin-resistant
Staphylococcus aureus (MRSA);
 methicillin-sensitive *S. aureus* (MSSA)
- Staphylococcus aureus* pneumonia, 107–129
 clinical features, 113
 epidemiology, 109–111
 pathogenesis, 112
 prevention of, 111–112
 prognosis, 113–114
 treatment of, 114–123
- stem cell transplant patients
 acute respiratory failure, 192
 fungal infections, 147, 150–151, 151
 antifungal prophylaxis, 159
 radiology findings, 201
- Stenotrophomonas maltophilia*, in VAP, 83, 239
- Streptococcus pneumoniae*
 in CAP, 6, 6
 diagnosis of infection, 204
 in HAP, 85, 85
 in HCAP, 5, 6, 6
 lower airway colonization by, 67
 in VAP, 95, 218

- Streptococcus viridans*, oropharyngeal
 colonization by, 24
 stress ulcer prophylaxis, 14, 26–27, 65
 subglottic suctioning
 continuous, 279–280
 VAP incidence affected by, 19, 219–220
 sucralfate, 27, 65
 suction systems
 in-line devices, cost study, 280
 VAP affected by, 13, 20–21
 sulbactam, 84, 133, 135, 136, 137, 224, 225
 sulfonamides, 161, 165
 supine position (of patient), effects, 17, 65,
 66, 67
 surveillance cultures, 45–46
 Swiss hospitals, cost studies, 277
 systemic antimicrobial prophylaxis, 14
- TAK-599 investigational antibiotic, 122
 teicoplanin, 84, 114, 116–117
 efficacy in critically ill patients 185
 pharmacokinetic/pharmacodynamic
 considerations, 181, 183
 telavancin, 119–120, 122–123
 tetracyclines, 117, 137, 179
 therapeutic drug monitoring (TDM), 187
 tigecycline, 85, 115, 117, 120–121, 138
 time-dependent antimicrobials, 176–177, 251
 pharmacodynamic determinants of
 efficacy, 176
see also beta-lactams; glycopeptides;
 linezolid; macrolides
 tobramycin, 85, 133, 225
 digestive decontamination using, 25, 221
 toxin production by bacteria, 250
 tracheal colonization, 67, 96, 218
 tracheostomy, recommendations, 13
 transfusion practice, effect on VAP, 28–29
 Transfusion Requirements in Critical Care
 (TRICC) trial, 29
 trauma patients
 case studies, 226–230
 pneumonia in, 69, 109–110, 215–234
 causative pathogens, 218–219
 pathogenesis, 217
 prevention strategies, 219–220
 risk factors, 215–217
 treatment of, 223–224, 225
 SDD therapy for, 220–222
- trimethoprim, 165
 trimethoprim/sulfamethoxazole
 combination, 165, 202
 tuberculosis, HRCT findings, 201, 202
 type III secretion system (TTSS), 97–98,
 250, 259, 261
- vancomycin, 84, 114, 115, 225
 AUC/MIC ratio, 115, 176
 lung penetration limitations, 84, 181
 pharmacokinetic/pharmacodynamic
 considerations, 181, 182, 183
 side effects, 115
 compared with linezolid, 84, 116, 117,
 253, 281–282
 vancomycin intermediate *S. aureus* (VISA),
 113, 115, 181
 vancomycin-resistant *Enterococcus* (VRE),
 114, 115
 effect of SDD therapy, 26
 vancomycin-resistant *S. aureus* (VRSA),
 115
 ventilator-associated pneumonia (VAP)
 antibiotic treatment, 101–103
 causal microorganisms, 44–45, 69, 83,
 94, 95, 107, 109, 133, 218–219
 in ARDS patients, 239–240
 clinical management strategy, 83
 clinical manifestations, 100
 cost saving per case prevented, 19,
 278, 280
 cost studies, 275–279
 definition, 11, 63, 235–236
 diagnosis, 15, 222–223
 in ARDS patients, 235–236
 clinical criteria, 80
 interpretation of microbiological
 information, 54, 81–82, 246
 role of microbiology laboratory, 43–62
 sampling techniques used, 45–50
 differential diagnosis between VAP and
 tracheobronchitis, 81
 histological characteristics, 71–73
 evolution phases, 72
 incidence, 79, 94
 in ARDS patients, 236–239
 mortality rates, 12, 87, 134, 247, 257
 ARDS patients, 241

- ventilator-associated pneumonia (VAP)
 (*Continued*)
 as multifocal/polymicrobial process, 44,
 50, 75
 pathogenesis, 12, 19, 24, 71, 96–99,
 112, 217
 post-mortem histological and
 microbiological studies, 73–75
 clinical implications, 75
 preventive strategies, 12–29, 219–220
 antibiotic policy, 27–28
 artificial airway management, 13–14,
 18–21, 219–220
 CDC HICPAC recommendations,
 13–14
 decolonization of aerodigestive tract,
 14, 24–27
 hand hygiene, 13, 16–17
 infection control, 16, 27
 mechanical ventilation management,
 13, 21–23
 non-pharmacologic strategies, 13–14,
 15–23
 patient positioning, 17–18, 219
 pharmacologic strategies, 14, 24–29
 reasons for non-adherence, 16
 rotational/kinetic bed therapy,
 14, 18
 staff education, 13, 16
 prognostic factors, 101
- recurrent, 257–272
 clinical impact, 261
 epidemiology, 259
 genetic predisposition, 263–264
 immunomodulatory strategies, 264–266
 pathogenesis, 258
 prevalent microorganisms, 259
 prevention measures, 262–263
 prognosis, 261–262
 risk factors, 260–261
 relapse compared with re-infection, 258
 risk factors, 12, 12, 99–100, 215–217
 empirical equation for trauma patients,
 216
- ventilator breathing circuits
 colonization of, 67–69
 with humidification systems, 13, 21–22
- ventilator circuit changes, VAP incidence
 affected by, 21
- viral pneumonia, 45
 HRCT findings, 201, 202
- volume of distribution
 consequences, 84, 185
 hydrophilic compared with lipophilic
 antibiotics, 179
 increased, factors affecting, 84, 186
- voriconazole, 157, 158
 adverse/side effects, 158
- WCK, 771 investigational antibiotic, 123